As of December 7, 2022 As you may know, the Board of Directors of electroCore, Inc. recently declared a stock dividend for our common stockholders. The dividend of Series A Preferred Stock is expected to be issued later this month to holders of record as of December 19, 2022.
First U.S. Food and Drug Administration (FDA) release for electroCore, a neuroscience and technology company - Hand-held, non-invasive, easy-to-use device provides new option for the approximately 400,000 Americans living with this rare but extremely debilitating headache disorder Basking Ridge,
ROCKAWAY, N.J. , July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working
ROCKAWAY, N.J. , Sept. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological
BASKING RIDGE, N.J: A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life.
Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injury ROCKAWAY, N.J. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data
ROCKAWAY, N.J. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been issued a National Code Number (CNK) in Belgium. CNK numbers are unique product code identifiers
gammaCore® Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients Basking Ridge, NJ, January 29, 2018 – electroCore, LLC (electroCore), a commercial-stage bioelectronic medicine company, announced today that it has received 510(k) clearance from
electroCore launches gammaCore Patient Registry (GPR) to provide access to hand-held, easy-to-use device for the acute treatment of pain associated with episodic cluster headache in adults Basking Ridge, NJ, July 18, 2017 – electroCore, a neuroscience and technology company dedicated to
BASKING RIDGE, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced its non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore TM , has been awarded a five-year Federal Supply Schedule Medical Equipment